As of June 30, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Here’s the latest list of major overbought players in this sector.
Definium Therapeutics Inc (NASDAQ:DFTX)
- On June 23, the company announced the pricing of a $700 million public offering of 20,588,236 shares at $34.00 per share. The company’s stock gained around 92% over the past month and has a 52-week high of $47.20.
- RSI Value: 89.2
- DFTX Price Action: Shares of Definium Therapeutics gained 3.6% to close at $46.55 on Monday.
Nurix Therapeutics Inc (NASDAQ:NRIX)
- On June 18, Baird analyst Joel Beatty maintained Nurix Therapeutics with an Outperform rating and raised the price target from $26 to $33. The company’s stock gained around 30% over the past five days and has a 52-week high of $24.03.
- RSI Value: 84
- NRIX Price Action: Shares of Nurix Therapeutics gained 4.2% to close at $23.85 on Monday.
- Edge Stock Ratings: 91.54 Momentum score.
Galectin Therapeutics Inc. (NASDAQ:GALT)
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.